2,863 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Tower Wealth Partners Inc.

Tower Wealth Partners Inc. acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,863 shares of the company’s stock, valued at approximately $223,000.

A number of other institutional investors and hedge funds have also made changes to their positions in AZN. Americana Partners LLC increased its holdings in shares of AstraZeneca by 1.4% in the third quarter. Americana Partners LLC now owns 28,413 shares of the company’s stock valued at $2,214,000 after purchasing an additional 395 shares during the period. Gladstone Institutional Advisory LLC grew its position in AstraZeneca by 7.4% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 2,893 shares of the company’s stock valued at $225,000 after buying an additional 199 shares during the last quarter. Focus Financial Network Inc. increased its stake in AstraZeneca by 9.1% in the 3rd quarter. Focus Financial Network Inc. now owns 5,295 shares of the company’s stock valued at $412,000 after buying an additional 441 shares during the period. Oak Ridge Investments LLC increased its stake in AstraZeneca by 7.2% in the 3rd quarter. Oak Ridge Investments LLC now owns 136,632 shares of the company’s stock valued at $10,645,000 after buying an additional 9,141 shares during the period. Finally, US Bancorp DE raised its position in AstraZeneca by 6.9% during the 3rd quarter. US Bancorp DE now owns 232,419 shares of the company’s stock worth $18,108,000 after buying an additional 14,965 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

AZN opened at $71.42 on Friday. The stock’s 50 day simple moving average is $79.17 and its 200 day simple moving average is $78.60. The stock has a market cap of $221.44 billion, a P/E ratio of 34.50, a P/E/G ratio of 1.32 and a beta of 0.47. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.